Orforglipron

Lilly's oral small-molecule GLP-1 agonist — FDA-approved in April 2026 (brand name Foundayo) for chronic weight management, the first GLP-1 pill without food or water timing restrictions.

Orforglipron is a GLP-1 receptor agonist, like semaglutide and tirzepatide — but it is a small molecule rather than a peptide, which is the whole point of it. Peptide GLP-1 drugs generally have poor oral bioavailability — oral semaglutide is a formulated exception, with strict food and water restrictions to make it work. Orforglipron is a non-peptide small molecule, so it survives the gut without those restrictions. It activates the same receptor: slowing stomach emptying, increasing satiety signalling, and improving glucose-dependent insulin release. Same target, same effects, without the needle — and manufacturing at tablet scale is far easier than peptide synthesis, which is why it matters for access as well as convenience.

A large Phase 3 program (ATTAIN) showing average weight loss up to roughly 12% at the highest studied dose over 72 weeks, plus A1c reduction — injectable-class results in pill form, now reflected in an approved label.

• STRONG for chronic weight management, which is its approved indication — FDA approved 2026-04-01 as the first small-molecule oral GLP-1 for that use, marketed as Foundayo. Glycaemic control is NOT an approved indication: HbA1c change appears as a trial endpoint, not a licensed use.
• The label reports the trial results plainly: in 3,127 adults without diabetes, mean body-weight change at week 72 was -11.1% at the approved highest dose against -2.1% on placebo; in 1,613 adults with type 2 diabetes it was -9.6% against -2.5%. No head-to-head trial against injectable agents exists, and the label itself warns that results across different trials cannot be directly compared — so this entry does not rank it against them.
• Gastrointestinal adverse effects — nausea, vomiting, diarrhoea, constipation — are the dominant tolerability issue and the main reason people discontinue, consistent with the class.
• The class carries a boxed warning for thyroid C-cell tumours based on rodent studies, with the human relevance not determined; it is contraindicated in medullary thyroid carcinoma and MEN2.
• Its labelled risks go well beyond nausea: pancreatitis, acute gallbladder disease, acute kidney injury from dehydration (including cases needing dialysis), serious hypersensitivity including anaphylaxis and angioedema, and complications of diabetic retinopathy. The label also advises against use in severe liver impairment. Note the eye warning here is diabetic retinopathy — the optic-neuropathy conclusion regulators reached applies to semaglutide medicines, not to this drug.

Orally active as a daily tablet, without the fasting and water requirements oral semaglutide needs — a genuine practical difference. It is a small molecule, so it does not carry peptide manufacturing constraints. Effects on gastric emptying can alter absorption of other oral medicines.

GLP-1-class GI effects (nausea, vomiting, constipation), and the label carries the class boxed warning for thyroid C-cell tumors — contraindicated with personal/family history of medullary thyroid carcinoma or MEN2. Now that an approved product exists, anything sold outside pharmacy channels is by definition not the approved drug and has no verifiable identity.

• Anyone with a personal or family history of medullary thyroid carcinoma, or with MEN2 — a labelled contraindication
• Anyone with a history of pancreatitis, without prescriber assessment
• Anyone pregnant, planning pregnancy or breastfeeding
• Anyone with severe gastrointestinal disease including gastroparesis
• Anyone obtaining it outside a lawful prescription

• Other oral medicines, whose absorption can be altered by slowed gastric emptying. The label also carries specific warnings involving CYP3A4 inhibitors and inducers, combined CYP3A4/OATP1B inhibition, simvastatin exposure, and reduced reliability of oral hormonal contraception during specified periods — all of which need a prescriber or pharmacist rather than a rule of thumb.
• Insulin and sulfonylureas, where hypoglycaemia risk rises in combination.
• Other GLP-1 agonists — stacking them is not a supported use and compounds gastrointestinal effects.
• Anaesthesia and sedation for procedures, where delayed gastric emptying raises aspiration risk and the anaesthetist needs to know.

Documented interactions with other things people research. A compound not listed here does not mean the combination is safe — only that no specific interaction is on file.

• This is a prescription medicine; use belongs with the prescriber who started it.
• Under supervision, what gets followed: gastrointestinal tolerability, which drives most discontinuation.
• Severe persistent abdominal pain — pancreatitis is a recognised class risk and needs urgent assessment, not observation.
• Any sudden vision change, given the labelled warning about complications of diabetic retinopathy.
• Any neck lump, difficulty swallowing or persistent hoarseness, given the thyroid boxed warning.

Weight regain after stopping is documented in randomised withdrawal and extension trials of semaglutide and tirzepatide. Whether the same magnitude and course apply to this drug specifically has not been established — plausible, not demonstrated. Either way it is a property of the treatment rather than a personal failure. Gastrointestinal effects resolve. Anyone stopping should do so with the prescriber, particularly if other glucose-lowering medicines are involved, since requirements change when the drug comes out.

US: FDA-approved prescription drug (April 2026). Non-pharmacy "research" versions are unapproved products with no provenance.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials
  Arch Endocrinol Metab, 2024

• Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity TreatmentN Engl J Med · 2025
• Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 DiabetesN Engl J Med · 2025
• Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with ObesityN Engl J Med · 2023
• Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participantsDiabetes Obes Metab · 2023
• Orforglipron in type 2 diabetes mellitus and obesity: an overviewExpert Rev Clin Pharmacol · 2025
• The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipronSci Transl Med · 2024
• Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysisObes Sci Pract · 2024
• Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetesDiabetes Obes Metab · 2023
• Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 studyLancet · 2023
• Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical TrialJAMA · 2026
• Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trialLancet · 2026
• Orforglipron2012